CymaBay Therapeutics Priced, Nasdaq: CBAY
Biotech developing treatments for gout and other metabolic and rare diseases.
Industry: Other
First Day Return: n/a
Industry: Other
CBAY
Biotech developing treatments for gout and other metabolic and rare diseases.
| IPO Data | |
|---|---|
| IPO File Date | 04/08/2014 |
| Offer Price | $5.50 |
| Price Range n/a | |
| Offer Shares (mm) | 4.0 |
| Deal Size ($mm) | $22 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 07/21/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $22 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Newark, CA, United States |
| Founded | 1988 |
| Employees at IPO | 15 |
| Website www.cymabay.com | |
IPO News for CymaBay Therapeutics
CymaBay Therapeutics (CBAY) Performance
